Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review

Area of Science:

• Cardiology
• Pharmacology
• Evidence-Based Medicine

Background:

• Uncertainty exists regarding the comparative safety and effectiveness of treatments for preventing thromboembolic complications in atrial fibrillation (AF).
• Existing treatments require further evaluation for their efficacy and safety profiles in managing AF-related risks.

Purpose of the Study:

• To compare the effectiveness of medical and procedural therapies in preventing thromboembolic events and bleeding complications in adults with nonvalvular AF.
• To synthesize evidence on the comparative safety and efficacy of anticoagulation strategies for stroke prevention in AF.

Main Methods:

• Systematic review and meta-analysis of English-language studies published from January 2000 to February 2018.
• Independent screening of citations and data abstraction by two reviewers to identify comparative studies on treatments for stroke prevention in nonvalvular AF.

Main Results:

• Direct-acting oral anticoagulants (DOACs) like dabigatran and apixaban were superior to warfarin in preventing stroke; rivaroxaban and edoxaban showed similar effectiveness.
• Apixaban and edoxaban demonstrated superiority in reducing major bleeding risk compared to warfarin; rivaroxaban and dabigatran were similar.
• DOACs showed consistent benefits across various subgroups, including patients with renal impairment, diabetes, and prior stroke, indicating broad applicability.

Conclusions:

• Direct-acting oral anticoagulants (DOACs) are at least as effective and safe as warfarin for patients with nonvalvular AF.
• DOACs provide similar benefits across multiple patient subgroups and appear safe and efficacious for a wide range of individuals with nonvalvular AF.